10 Best Performing Stocks To Own For 2014

Shares of American Airlines (AAL) took flight leading up to its merger with US Airways. Is the ride about to get bumpier?

Bloomberg

Barclays’ David Fintzen and Isaac Husseini say American Airlines shares could start to feel more turbulence. They write:

On the technical side, the stocks are historically volatile and prone to relative underperformance. Even the best performing emergence (LCC as old US air emerged from bankruptcy and closed the America West merger) saw 40% relative out-performance in the first months quickly wiped out, before seeing the shares recover 6-7 months post emergence and solidly out-perform peer airlines in the months following. [Delta Air Lines (DAL)], NWA and UAUA (the pre-merger United� all saw reasonably large post emergence sell-offs, ranging from ~10% ([Delta]), 20% (NWA) and the extreme of ~60% relative declines for UAUA.

Top 5 Defense Companies To Invest In Right Now: Amedisys Inc(AMED)

Amedisys, Inc., a health care company, provides home health and hospice services primarily in the United States. It operates in two segments, Home Health and Hospice. The Home Health segment offers various services in the homes of individuals who may be recovering from an illness, injury, or surgical procedure. This segment?s services include skilled nursing, home health aides, physical and occupational therapy, speech therapy, and medical social services; and chronic care clinical programs for patients with chronic diseases, such as cardiovascular, respiratory, diabetes, behavioral health, rehabilitative, and medical surgical conditions. The Hospice segment provides care that is designed to offer comfort and support for those who are facing a terminal illness, such as heart disease, pulmonary disease, dementia, Alzheimer?s, HIV/AIDS, or cancer. As of December 31, 2011, the company owned and operated 440 Medicare-certified home health care centers, 87 Medicare-certified hospice care centers, and 2 hospice inpatient units in 41 states within the United States, the District of Columbia, and Puerto Rico. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Advisors' Opinion:

• [By Monica Gerson]

  Amedisys (NASDAQ: AMED) shares jumped more than 29% on Friday after the company issued Q2 outlook. The company projected its Q2 earnings of $0.15 to $0.20 per share on revenue of $300 million to $305 million. Amedisys shares surged 5.33% to $18.39 in after-hours trading.

10 Best Performing Stocks To Own For 2014: Mostostroy No6 OAO (MSTF)

Mostostroy No6 OAO (Mostostroitel��yi trest No 6 OAO or Bridge Construction Trust N 6 OJSC) is a Russia-based company engaged in the construction industry. Its services portfolio includes the design, construction, reconstruction and renovation of bridges, railways, highways, tunnels and subways, nuclear and thermal power stations, residential and industrial facilities, among others. Mostostroitel��yi trest No 6 OAO provides its services mainly to companies engaged in the transportation, hydraulic engineering, industrial, civil and nuclear construction sectors and its customers include ROSATOM and Russian Railways, among others. The Company operates through 10 branches, as well as two representative offices, located in Moscow and Sochi. In addition, it has five wholly owned subsidiaries. As of March 4, 2011, the Company�� major shareholder was Malakhit OOO with a stake of 19.85%. Advisors' Opinion:

• [By Tom Taulli]

  But again, the most glaring red flag is the valuation of GOOG stock. Shares of Google stock are currently trading at a P/E ratio of 30, which is certainly rich. Consider that�Apple (AAPL) and �Microsoft (MSTF) sport multiples of only about 14. These companies also have decent dividend yields.

10 Best Performing Stocks To Own For 2014: Towers Watson & Co (TW)

Towers Watson & Co. operates as a global professional services company that provides human capital, and financial consulting services worldwide. The company operates in four segments: Benefits, Risk and Financial Services, Talent and Rewards, and Exchange Solutions. The Benefits segment offers benefits consulting and administration services, such as retirement solutions, which support organizations in designing, managing, administering, and communicating retirement plans; and health and group benefits that provides advice on the strategy, design, financing, delivery, ongoing plan management, and communication of health and group benefit programs. This segment also offers its technology and administration solutions to deliver benefit outsourcing solutions; and international consulting services, which provide expertise in dealing with international human capital management and related benefits, and compensation advice. The Risk and Financial Services segment offers risk cons ulting and financial modeling software solutions primarily to the insurance industry; reinsurance and insurance brokerage services; and investment consulting and solutions covering investment strategy risk assessment, asset allocation, and investment manager selection to institutional investors. The Talent and Rewards segment provides executive compensation advisory services; employee rewards, talent management, and communication and change management services; and data, analytics, survey, and technology solutions. The Exchange Solutions segment operates the private Medicare insurance exchange in the United States that enables employers to transition their retirees to individual, defined contribution health plans. The company was formerly known as Watson Wyatt Worldwide, Inc. and changed its name to Towers Watson & Co. in January 2010 as a result of merging with Towers, Perrin, Forster & Crosby, Inc. Towers Watson & Co. was founded in 1871 and is headquartered in New York, N ew York.

Advisors' Opinion:

• [By Ben Levisohn]

  Towers Watson�(TW) has dropped 0.5% to $102.49 after it was cut to Neutral from Overweight at JPMorgan. It was also upgraded to Buy from Hold at Deutsche Bank.

• [By Dan Caplinger]

  The real test for Obamacare
  In any event, the biggest challenge that Obamacare faces is getting its Health Insurance Marketplace up and running by Oct. 1. Although private exchanges from Marsh & McLennan (NYSE: MMC  ) subsidiary Mercer as well as Towers Watson (NYSE: TW  ) have done a good job of getting Aetna, UnitedHealth, and other popular insurers to participate in their programs, the reception that public exchanges have gotten has been far less favorable. Without a smooth launch in less than three months, Obamacare could find itself facing much greater criticism than it is today.

• [By Keith Speights]

  Towers Watson (NYSE: TW  ) wasn't far behind in announcing several large health insurers signing up to participate in its OneExchange private health insurance exchange. Participating insurers include Aetna, Anthem, Kaiser Permanante, and UnitedHealthcare. Towers Watson also recently bought Extend Health, which runs the largest private Medicare exchange in the nation.�

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Towers Watson (NYSE: TW  ) , whose recent revenue and earnings are plotted below.

10 Best Performing Stocks To Own For 2014: Northrim BanCorp Inc(NRIM)

Northrim BanCorp, Inc., through its subsidiaries, which provides a range of banking products and services to businesses, professionals, and individuals in Alaska. Its deposit services include noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts. The company?s loan portfolio comprises commercial and real estate lending, construction and land development lending, and consumer loans. Northrim BanCorp also offers other customer services, including telebanking, faxed account statements, Internet banking, automated teller services, personalized checks at account opening, overdraft protection from a savings account, extended banking hours, commercial drive-up banking with coin service, automatic transfers and payments, wire transfers, direct payroll deposit, electronic tax payments, automated clearing house origination and receipt, and cash management services. In addition, it provides investment advisory, insurance br okerage, trust, and wealth management services. As of December 31, 2009, the company operated 11 branches, including 7 in Anchorage, 2 in Fairbanks, and 1 each in Eagle River and Wasilla. Northrim BanCorp, Inc. was founded in 1990 and is headquartered in Anchorage, Alaska.

Advisors' Opinion:

• [By GURUFOCUS]

  Northrim BanCorp Inc. (NRIM) operates as the bank holding company for Northrim Bank that provides commercial banking products and services to businesses, professionals, and individuals primarily in Alaska. August 16th the company increased its quarterly dividend 13% to $0.17 per share. The dividend is payable Sept. 13 to shareholders of record as of the close of business on Sept. 5, 2013. The yield based on the new payout is 2.8%.

10 Best Performing Stocks To Own For 2014: Genomic Health Inc (GHDX)

Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.

Oncotype DX Platform

The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.

Oncotype DX Breast Cancer Test

To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.

In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.

Oncotype DX Colon Cancer Test

The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.

The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.

Advisors' Opinion:

• [By John Udovich]

  Small cap cancer diagnostic stock�Myriad Genetics, Inc (NASDAQ: MYGN) jumped to a five year high on Wednesday�thanks to good�news that the�government will be paying a heftier reimbursement for its main test than previously feared, meaning its worth taking a closer look at the stock along with small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should also mention that Myriad Genetics has been in our SmallCap Network Elite Opportunity (SCN EO) portfolio since early February and we are now up some 32.5% since then ��thanks in part to the shorts being put in a short squeeze.

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By Keith Speights]

  Genetic testing stands out as one current example of how scientific advances can help reduce medical costs. Genomic Health (NASDAQ: GHDX  ) makes genetic diagnostic tests for�breast, colon, and prostate cancer. Half of the patients diagnosed with prostate cancer each year actually have a very low risk of the cancer progressing. However, 90% of these low-risk patients still undergo surgery or radiation -- at a cost of tens of thousands of dollars per patient. Genomic Health's genetic test helps identify which patients really need more extensive treatment and holds the potential to reduce overall costs.

10 Best Performing Stocks To Own For 2014: Drinks Americas Holdings Ltd (DKAM)

Drinks Americas Holdings, Ltd., incorporated in February 14, 2005, develops, produces, markets and/or distributes alcoholic and non-alcoholic beverages for sale primarily in the continental United States. Through its majority-owned subsidiaries, Drinks imports, distributes and markets premium wine and spirits and alcoholic beverages to beverage wholesalers throughout the United States and internationally. The alcoholic products distributed by the Company are KAH Tequila, Old Whiskey River Bourbon (R), Rheingold Beer, Damiana, a Mexican liqueur, Mexicali Beer, Agave 99, Chili Devil Beer, Crazy PigAle and Red Pig Ale. In June, 2011 the Company acquired the rights to distribute and market existing brands and products from Fabrica De Tequilas Finos S.A. de C.V. (Finos) and Cervecera Mexicana, S. de R.L. de C.V. (Cerveceria). In June 2011, the Company acquired the rights to distribute and market existing brands and products through a licensing agreement with Worldwide Beverage Imports, LLC, (WBI). On November 2, 2011, the Company acquired worldwide licensing and distribution rights on both the spirits and beer products owned or licensed by WBI. In June 2013, the Company announced the development of Drinks Americas Consumer Beverage Consulting Division.

The Company owns, distributes or licenses or collects royalties from a number of Spirits Brands to include Old Whiskey River Bourbon, Damiana Liqueur and Rheingold Beer. The Company owns 25% interest in Old Whiskey River Distilling Company, LLC which owns or licenses the related trademarks and trade names associated with the Old Whiskey River products.

The Company compets with Diageo, Allied Domecq, Pernod Ricard, Brown-Forman and Bacardi & Company, Ltd.

Advisors' Opinion:

• [By Peter Graham]

  Last Friday, small cap stocks MedCAREERS Group Inc (OTCMKTS: MCGI), USmart Mobile Device Inc (OTCMKTS: UMDI) and Drinks Americas Holdings, Ltd (OTCMKTS: DKAM) were all over the place with the first two sinking 54% and 48.05%, respectively, while the last one rose 10.81%. It should be mentioned that all three small cap stocks have been the subject of paid promotions albeit none of these stocks have been over promoted. So where can investors and traders expect these stocks to head this week? Here is a quick look at what you might expect:

• [By Bryan Murphy]

  Say whatever you want about Drinks Americas Holdings, Ltd. (OTCMKTS:DKAM), but one thing is undeniable... this company is producing a lot of revenue despite being a very small company. More specifically, the DKAM market cap is abnormally low relative to the sales figures the company is putting up.

• [By Peter Graham]

  Small cap stocks Drinks Americas Holdings, Ltd (OTCMKTS: DKAM), 7 Star Entertainment Inc (OTCMKTS: SAEE), Rising India Inc (OTCMKTS: RSII) and Big Tree Group Inc (OTCMKTS: BIGG) have all been attracting attention thanks to paid promotions. Of course, there is nothing wrong with properly disclosed and paid for promotions or investor relation activities, but they can backfire on unwary investors and traders alike. So are stock promoters blowing a bunch of hot air regarding these four small cap stocks or are they actually potential winners? Here is a quick reality check to help you decide:

  Drinks Americas Holdings, Ltd (OTCMKTS: DKAM) Has One of the Top Beers of 2013

  Small cap Drinks Americas Holdings mission is to identify and invest the majority brand-building resources on beers and spirits with the greatest growth potential. Currently, Drinks Americas is the exclusive United States broker for leading premium authentic Mexican beers currently available in over 32 states, hundreds of chain retailers and restaurants and is on target to be the leading broker for this growing category in each of the markets in which it operates. On Friday, Drinks Americas Holdings rose 2.15% to $0.0095 for a market cap of $280,110 plus DKAM is down 89.3% over the past year and down 94.6% over the past five years according to Google Finance.

10 Best Performing Stocks To Own For 2014: Albany International Corp (AIN)

Albany International Corp., incorporated in 1895, is an advanced textile and material processing company. The Company�� business is a producer of custom-designed fabrics and belts essential to paper and paperboard production. The consumable fabrics are used to manufacture all grades of paper from lightweight paper to heavyweight containerboard. The Company has five segments: Paper Machine Clothing segment (PMC), Engineered Composites (AEC), Albany Door Systems (ADS), Engineered Fabrics (EF) and PrimaLoft Products. Albany International supplies the worldwide pulp and paper industry, as well as other process industries, with technologically advanced structured materials and related services. The Company maintains manufacturing facilities in Brazil, Canada, China, France, Germany, the United Kingdom, Italy, Mexico, New Zealand, South Korea, Sweden, Turkey, and the United States. On January 11, 2012, the Company sold its assets in the Albany Door Systems (ADS) segment to ASSA ABLOY AB.

Paper Machine Clothing

During the year ended December 31, 2011, the Paper Machine Clothing (PMC) segment accounted for 81% of its total revenues. The Company designs, manufactures, and markets paper machine clothing for each section of the paper machine. PMC consists of permeable and non-permeable continuous belts of custom-designed and custom-manufactured engineered fabrics that are installed on paper machines and carry the paper stock through each stage of the paper production process. PMC products are consumable products of technologically design that utilize polymeric materials in a complex structure.

The Paper Machine Clothing segment�� products include forming, pressing, and dryer fabrics, and process belts. A forming fabric assists in sheet formation and conveys the very wet sheet (more than 75% water) through the forming section. Press fabrics are designed to carry the sheet through the press section, where water is pressed from the sheet as it passes through the press ni! p. In the dryer section, dryer fabrics manage air movement and hold the sheet against heated cylinders to enhance drying. Process belts are used in the press section to increase dryness and enhance sheet properties, as well as in other sections of the machine. The Company sells its PMC products directly to customer end-users, which are paper industry companies, some of which operate in multiple regions of the world. Its products, manufacturing processes, and distribution channels for PMC are substantially the same in each region of the world, in which the Company operates.

The Engineered Composites (AEC)

The Engineered Composites segment (AEC) provides custom-designed advanced composite structures based on technology to customers in the aerospace and defense industries. AEC�� is engaged in development program relates to the LEAP-X engine being developed by CFM International. Under this program, AEC is developing a family of composite parts, including fan blades, to be incorporated into the LEAP-X engine.

PrimaLoft Products segment

The PrimaLoft Products segment includes sale of insulation for outdoor clothing, gloves, footwear, sleeping bags, and home furnishings. This segment has sales operations in the United States, Europe, and Asia, through which it sells products produced by third parties. This segment also generates a portion of its income as royalties from the licensing of its intellectual property.

Engineered Fabrics segment

The Engineered Fabrics segment supplies consumable fabrics used to process paper pulp, as well as fabrics used in a range of industries other than papermaking. These other products include belts used to make non wovens, fiber cement building products, roofing shingles and corrugated sheets used in boxboard, as well as belts used in tannery and textile applications.

Advisors' Opinion:

• [By Seth Jayson]

  Albany International (NYSE: AIN  ) reported earnings on May 1. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q1), Albany International met expectations on revenues and missed estimates on earnings per share.

• [By Seth Jayson]

  There's no foolproof way to know the future for Albany International (NYSE: AIN  ) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result.